Chronic lymphocytic leukemia (CLL) cells require complex microenvironmental and immunologic interactions to survive and proliferate. Such interactions might be best recreated in animal models; however, this needs extensive verification. We therefore investigated the composition of the T-cell compartment in the El-TCL1 transgenic mouse, currently the most widely used murine model for CLL. Immunophenotyping and transplant approaches were used to define T-cell subsets at various stages of CLL. Analogous to human CLL, we observed a skewing of T-cell subsets from naive to antigen-experienced memory T cells that was more pronounced in lymph nodes than in blood. Transplantation of CLL into non-transgenic recipients was feasible without immunosuppression in a pure C57BL/6 background and resulted in the prominent skewing of the T cells of the recipient mice. Both in spontaneously developed CLL and in the transplantation setting, a loss in T-cell receptor diversity was observed, with a relevant number of clonal T-cell populations arising. This suggests that antigen-dependent differentiation toward the T memory pool is initiated by murine CLL cells. In summary, we validate the TCL1 transgenic mouse model for analysis of T-cell phenotypes and suggest a CLL-dependent antigen-driven skewing of T cells in these mice.
Introduction
In the past decade, it has emerged that human chronic lymphocytic leukemia (CLL) cells are engaged in intricate interactions with the microenvironment (reviewed in CaligarisCappio and Ghia 1 and Ghia et al. 2 ). These interactions seem to modify aspects central to disease pathophysiology, such as the regulation of cell proliferation or cell death, and the interplay with components of the immune system. While CLL cells from the periphery appeared to be relatively inert, more recently CLL was shown to have higher proliferative rates in vivo than previously thought. [3] [4] [5] Currently, proliferation and maintenance of the CLL clone is thought to occur in organized structures termed proliferative centers, 1 where an optimal combination of accessory cells and signals converge to help CLL cells survive and expand. CD4 T cells appear to be an integral component of such proliferative units. 6 Indeed, T-cell abnormalities occurring alongside CLL have been observed for a long time 7, 8 and, more recently, an aberrant interaction between T cells and CLL cells has been described. 9 Our own previous work suggested that in human CLL the T-cell subset composition is severely skewed and that this was associated with stage, progressive disease, and time to development of a treatment indication. 10 These data suggested that an accumulation of antigen-experienced T cells in the memory compartment were somehow associated with a more aggressive disease course.
There are certain limitations to investigating interactions between CLL and T cells in the human system. Access to tissue from lymph nodes or other lymphatic organs is restricted, and the ex vivo recreation of a complete microenvironment for immune interactions is difficult. Thus, we set out to ask whether an animal model might be suitable for analyzing such an interplay. The Em-TCL1 transgenic mouse model was chosen for this purpose. While currently available xenograft models allow the study of only a few cycles of proliferation in vivo, 11 TCL1 transgenic mice develop a murine CLL that goes on to a fullblown clonal and lethal leukemia. 12 The function of Tcl1 in cellular signaling is not entirely clear, comprising functions in modulation of AKT signaling, but also AKT-independent mechanisms (for a review see Noguchi et al. 13 and Teitell 14 ). However, on a clinical level, Tcl1 itself has been demonstrated to be an important determinant of CLL fate in the human system 15 and was predictive of time to progression after FCR chemotherapy. 16 The TCL1 transgenic murine model is the most widely validated murine CLL model to date. It has been shown to display features of unmutated CLL disease, with B-cell receptor characteristics akin to human disease, 17 and also showed epigenetic changes similar to human CLL. 18, 19 The model has been successfully used to establish the role of signaling pathways important for CLL development, in experiments using crosses with genetically modified mice. [20] [21] [22] Regarding the CLLFT-cell interplay, it was demonstrated that a shift in gene expression profiles similar to that reported in human CLL was also observed in the TCL1 transgenic CLL model. 23 Thus far, however, no data on the subset composition of the T-cell compartment has been reported in these mice. We therefore asked whether TCL1 transgenic mice would recapitulate the qualitative shifting of T-cell subsets we had observed in human CLL, and established for the first time evidence that such changes may directly be induced by CLL cells.
Materials and methods

Mice
Em-TCL1 transgenic mice were kindly provided by C Croce (Columbus, OH, USA) on a mixed B6C3 genetic background and were backcrossed for 410 generations to C57BL/6 mice. Genotyping of mice was performed as previously described. 12 Experiments were performed under the approval from the central Austrian animal ethics committee. Mice were followed for signs of illness and killed when moribund or at the indicated time points. Samples for histology and flow cytometric analysis of tumor tissue were collected. Transplants were performed by injection of 2 Â 10 7 white blood cells from the spleens of animals with established CLL disease into the peritoneal cavity (PC) of 6-8-week-old C57BL/6J wild-type (WT) mice or C57BL/ 6-Tg(ACTB-EGFP)131Osb/LeySopJ mice (Jackson Laboratories, Bar Harbor, ME, USA), which carry the green fluorescence protein (GFP) transgene under the control of the chicken b-actin promoter and cytomegalovirus enhancer.
Flow cytometry
All antibodies were purchased from BD Biosciences (San Diego, CA, USA) or Biolegend (San Diego, CA, USA). Single cell suspensions of various lymphoid organs were stained with antibodies toward CD19 (6D5 or ID3), CD5 (53-7.3), CD3 (17A2), CD4 (H129.19 or RM4-5), CD8 (53-6.7), CD25 (PC61) and CD44 (IM7) as indicated. Cells were measured on an FC500 Beckman Coulter flow cytometer, and data were analyzed using CPX 1.0 Software (Beckman Coulter, Werfen Austria, Vienna, Austria).
TCR spectratyping
CD4 þ and CD8 þ T-cell populations were isolated by magnetic bead sorting (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). RNA was extracted from sorted T cells using the Ambion RNAqueous kit (Applied Biosystems, Brunn am Gebirge, Austria). In all, 0.5-1.0 mg of total RNA was used to generate cDNA (complementary DNA) using the iScript cDNA synthesis kit (Bio-Rad Laboratories Ges.m.b.H., Vienna, Austria). cDNA samples were amplified in 35 cycles of PCR using a panel of 24 TCR BV-specific 5 0 primers and a TCR BC-specific 3
0
WellRED-D4PA-labeled primer (PROLIGO Primers & Probes, Sigma-Aldrich, Vienna, Austria) (Supplementary Table 1 ). 24 Spectratyping was performed using a Genetic Analysis System CEQ 8000 (Beckman Coulter). The clonality of each TCR BV family was determined semiquantitatively from the distribution of the CDR3 lengths obtained (Supplementary Methods; Supplementary Figure 1 ).
Statistics
All statistical analyses (Supplementary Methods) were performed using GraphPad Prism 5.0 Software (GraphPad Software Inc., La Jolla, CA, USA).
Results
Em-TCL1 transgenic mice developing CLL display altered T-cell numbers and skewed subset distribution similar to human CLL
We analyzed the T-cell compartment of aged TCL1 transgenic mice that had developed signs of illness and were confirmed to have established CLL with high tumor load compared with WT age-matched controls ( Figure 1a ). The absolute number of T cells was significantly increased in the peripheral blood of the leukemic TCL1 transgenic mice, reaching a median value of 3.9 Â 10 6 cells as compared with 1.0 Â 10 6 total T cells in the blood of non-transgenic littermate controls (Figure 1b) . Such an increase in T-cell numbers has been reported in human CLL. 25, 26 The observed increase in T cells in our mice was mostly due to an increase in CD8 þ T cells, which accounted for B72% of all T cells in the transgenic mice, but only B50% in WT controls. A similar trend was observed in CLL infiltrated lymph nodes and spleen, but this did not reach statistical significance (Figures 1c and d and data not shown).
We then determined the subset composition of the T cells and used flow cytometry to first distinguish between CD4 þ and CD8 þ subsets, and then characterize the naive, memory and effector T cells using CD44 and CD25 expression as markers [27] [28] [29] (for a schematic see Figure 2a ). Similar to our earlier observation in human CLL, 10 we found a decrease in the relative numbers of naive T cells, from 80 to 70% in the CD4 þ compartment, and a concomitant increase in the relative numbers of antigen-experienced memory T cells and from 15 to 25% in the blood of TCL1 transgenic mice with established CLL compared with non-transgenic littermates (Table 1 ; Figures 2b-e). The effect was more pronounced in the CD8 þ T-cell subset, where the relative numbers of naive T cells was decreased to 39% compared with 69% in the WT mice, and the relative numbers of memory T cells increased to 61% from 27% in the controls (Table 1 ; Figures 2b-e). Furthermore, the observed shift from naive T cells to antigen-experienced memory T cells was more evident in lymph node tissue than in peripheral blood (Table 1 ; Figures 2b-e), where the CD4 þ population consisted of 48% naive and 48% antigen-experienced cells (compared with 80% naive and 17% memory cells in the WT controls), and the CD8 þ compartment comprised 14% naive (WT 70%) and 86% antigen-experienced cells (WT 27%). The data suggest that the composition of T-cell subsets may be even more skewed in those lymphoid compartments where the interaction between CLL cells and the T cells is more intense. 
Changes in the T-cell compartment develop alongside the expansion of CLL-like pre-tumor cells in tissues
Mice carrying an Em-TCL1 transgene develop a progressive CLL-like clonal disease to which they ultimately succumb starting at 250-350 days of age. A temporal and local establishment of the CD5/CD19 hyperplasia has been demonstrated with the accumulation of these cells first in the PC and later expanding into other lymphoid tissues. 12 We exploited this predictable disease course by analyzing the changes in the T-cell compartment in pre-tumor mice with respect to the CD5/ CD19 B cell load in the different lymphoid organs. The T-cell subset composition was comparable to that of non-transgenic age-matched mice in tissues not yet affected by the CD5/CD19 hyperplasia. However, we detected a relevant shifting of the T-cell population, from naive to experienced cells, in tissues that already had a detectable CD5 þ B-cell hyperplasia (Figures 3a  and b) . Indeed when looking for a correlation between the presence of CD5/CD19 þ B cells and the percentage of T memory cells in lymph nodes, where we observe the most robust changes in the T-cell compartment, we found a significant positive correlation for both CD4 þ and CD8 þ cells (Figures 3c and d) .
Em-TCL1 transgenic CLL cells are able to rapidly establish CLL in immunocompetent recipients
Previously reported transplantation models of Tcl1-induced murine CLL were performed either using immunodeficient mice or using mice of a mixed background. Analyses of the effects of a transplanted tumor on the recipient immune system precludes the use of immunodeficient recipients, and transplantation experiments in a mixed genetic background are difficult to interpret especially when focusing on immunologic parameters. We have extensively backcrossed our mice to C57BL/6 in order to avoid such obstacles. Injection of 6-8-week-old nontransgenic C57BL/6 mice with splenocytes from mice with established CLL resulted in reliable engraftment with recipient mice falling ill at a median age of 136 days (range 92-229 days or 3-6 months) (Supplementary Figure 2) . This represents a median latency period of 83 days after tumor engraftment, which is 247 days earlier than the spontaneous development of Tcl1-driven CLL in the transgenic mice. Thus, the transplantation model effectively shortens the latency period of the disease, suggesting that this system may also be useful as a high turnover drug discovery tool.
Transplanted CLL cells quickly induce T-cell subset changes similar to the situation of spontaneous CLL development
We analyzed mice in the transplantation cohort that had developed CLL (Figure 4a ) and found that the skewing of the T-cell compartments observed in spontaneously developing TCL1-transgenic CLL was recapitulated in the transplanted mice. WT (non-transgenic) mice and TCL1 transgenic mice aged 3-6 months displayed similar T-cell subset distribution in the blood (data not shown) and lymph nodes, with relatively more naive CD4 þ and CD8 þ T cells (B84%) than antigen-experienced memory and effector T cells (B14%) (Figures 4b and c) . Similarly, WT mice that had been transplanted with healthy splenocytes (Tx-ctrl) also retained a WT T-cell pattern (B88% naive, B9% antigen-experienced), demonstrating that the transplantation process per se does not change the T-cell repertoire (Figures 4b and c) . However, mice transplanted with Figure 2 Skewing of T-cell subsets toward an antigen-experienced population in leukemic mice. The T-cell subset distribution in various lymphoid organs of leukemic TCL1 transgenic mice was compared with that of non-transgenic littermate controls. (a) Determination of T-cell subsets. CD4 þ and CD8 þ subsets were discriminated based on the surface expression of these markers along with CD3. The population was further separated into naive, memory and effector T cells based on surface expression of CD25 and CD44: Naive, CD25À CD44À; Memory CD25À CD44 þ ; Effector, CD25 þ CD44 þ . Distribution of naive and antigen-experienced (memory þ effector) T cells in both the CD4 þ compartment (b) and CD8 þ compartment (c) in the peripheral blood. T-cell subset composition of the CD4 þ (d) and CD8 þ (e) compartments in the lymph nodes. T cells in murine CLL J Piñón Hofbauer et al murine CLL cells that had subsequently developed CLL had significantly higher percentages of CD4 þ and CD8 þ T memory cells (B72%) and a significantly lower proportion of naive T cells (B26%) compared with age-matched controls. Furthermore, the extent of skewing from a WT T-cell pattern to an experienced T-cell pattern was similar in mice with established CLL in the transplant and primary disease models (Figures 4b and c ; TCL1 tg 48 months vs Tx-CLL). Again the skewing was more pronounced in lymph nodes than in peripheral blood (not shown). The data suggest that a fully transformed clone may be more rapid and efficient in inducing T-cell changes than the slowly evolving counterpart in the TCL1 transgenic spontaneous model (Figures 4b and c; TCL1 tg 3-6 months vs Tx-CLL).
In our model, we injected unsorted splenocytes from CLLbearing mice into recipients because the additional stress of CLL cell isolation procedures had previously precluded successful transplants in our hands. This, however, carries the possibility that the already skewed T-cell populations from the donor mice could engraft in the recipients and expand to create the skewed repertoire observed. We thus used GFP-transgenic recipients to determine the origin of the skewed T cells. In these experiments, we could clearly demonstrate that all CLL cells were derived from the GFP-negative donor, whereas all T cells (as well as non-CD5 þ B cells) were derived from the GFP-positive recipients ( Figure 5) . Thus, injection of CLL cells into immunocompetent WT recipients is able to rapidly induce extensive T-cell subset changes in the recipient T-cell compartment.
T cells in Tcl1-induced CLL are clonally skewed and this is recapitulated in transplanted recipients
In principle, the introduction of changes into the T-cell compartment may rely on factors such as cytokines, which may non-specifically drive such alterations. However, it may also involve antigen-specific interactions between CLL cells and T cells on a clonal level. Since a clonally skewed T-cell repertoire has previously been reported in human CLL, 30, 31 we wanted to determine whether the same could be observed in our mouse model. We sorted CD4 þ and CD8 þ T cells from WT mice, as well as from mice with spontaneously developed or transplanted CLL, and performed CDR3 spectratyping analysis on cDNA from the T cells to determine the pattern of clonality per TCR family (Supplementary Methods). Overall, we found few oligoclonal or monoclonal representation in T cells from WT mice (Figures 6a and b) . By comparison, mice that had spontaneously developed CLL displayed a much less diverse T-cell compartment, with more TCR families skewed toward a clonal pattern. In mice with established transplanted CLL, the observed T-cell compartment was even more skewed ( Figures  6a and b) , in line with the pronounced effect on the T-cell subset T cells in murine CLL J Piñón Hofbauer et al distribution we had observed. In our opinion, this suggests that relevant parts of the T-cell skewing observed in murine CLL may be CLL-induced and antigen-driven.
Discussion
We demonstrate that the TCL1 transgenic mouse model faithfully recapitulates the skewing of T-cell subsets in CLL, a phenomenon we had previously observed in human CLL. 10 In this work, we had detailed the shift from a naive to an antigen-experienced memory T-cell repertoire in human CLL on the CD4 þ cell side. The observed changes in CD4 þ composition were associated with more aggressive disease characteristics, and antigen-experienced CD4 þ cells were able to protect autologous CLL cells from dying in vitro, suggesting a potential pathophysiologic relevance of our observations. A similar skewing was observed in human CD8 þ T cells (I Tinhofer, unpublished observation). With extensive backcrossing to a pure genetic background, thereby excluding genetic disparities between mice, we can now demonstrate that T cells in the murine model are skewed in a manner highly similar to that observed in the human system, thereby validating the model 
T cells in murine CLL
J Piñón Hofbauer et al also on this level. Importantly, the degree of T-cell subset skewing was always more pronounced in lymph node tissue compared with blood, suggesting a more intense CLLFT-cell interaction in this tissue, as has been reported in human CLL, and highlighting an essential strength of the mouse systemFthe ease with which interactions in all lymphoid organs can be analyzed.
Our findings also demonstrate definitively that the T-cell changes can be driven by the CLL clone itself. The evidence comes from two levels: (1) from correlative observations, where T-cell changes appear in only those tissues where the CLL-like hyperplasia begins in young animals and are more pronounced with increasing tumor load, and (2) from the direct induction of T-cell changes in a transplantation setting. Previous studies reported the changes in gene expression patterns introduced into the T cells of mice injected with CLL cells in a short-term transplant setting on a mixed genetic background. However, no long-term effects or successful disease establishment following transplantation were described. Whether these changes in T-cell gene expression observed were temporary or permanent was not ascertained, nor could the contribution of input T cells from the donor be excluded. With our data, however, we can exclude that the changes in T-cell composition could have been affected by immune reactions triggered by differences in HLA between donors and recipients since we present the first transplantation data on a pure inbred genetic background. We show that the changes in the T-cell subset composition are long-term, and that the altered T-cell compartment is recipient-derived, thus excluding that the antigen-experienced T cells from the donor may proliferate in the recipients to generate the observed phenotype. Our results tend to argue that the changes in the global gene expression pattern that have been reported when profiling bulk preparations of CD4 þ or CD8 þ cells are associated with the altered T-cell compartment composition and reflect changes in pathways associated with T-cell differentiation and activation states, rather than global expression changes independent of functional subsets.
While our correlative data set is compatible with the idea that certain changes in T-cell composition may be a prerequisite for colonization of a tissue by the CD5/CD19 þ cells, the transplantation experiments suggest that CLL very effectively and quickly induces T-cell differentiation in immunocompetent recipients that have never been in contact with the clone before. This highlights a particular strength of our model over the use of immunodeficient or partially lymphodepleted mice, where a step of homeostatic proliferation may allow the donor T cells to more effectively grow in the recipient. In such a case, a quick change of T-cell differentiated states and a highly skewed T-cell repertoire would be expected. Indeed, despite not using any step of lymphodepletion in our recipients, we found a highly skewed and partially clonal repertoire in the antigen-experienced T cells, suggesting that a limited number of antigenic interactions have contributed to the selection of the repertoire. These determinants were most likely contributed by the CLL clone itself since, apart from this, the antigenic environment was otherwise identical, and skewing was only observed in mice injected with CLL-containing splenocytes. Our data does not exclude that the modified T-cell system may provide essential clues for the development of CLL in this setting. In fact, given that we had previously observed that human CLL cells were partially protected from cell death in vitro by co-incubation with antigen-experienced memory T-cell populations, it is very tempting to speculate that such a population may be directly recruited by clonally selecting T cells with an antigeninteraction directly contributed by the CLL clone.
In summary, our data highlight the need to scrupulously validate individual aspects of a murine model before using the model for further exploration with the intent of modeling human disease. Importantly, we show that CLL is able to efficiently drive large-scale changes in a (naive) T-cell compartment that are most likely antigen-driven and associated with the differentiation of T cells into the memory compartment. The insight into immune regulation induced by CLL gained from this murine model may ultimately help to better understand the immune defect observed in CLL, as well as to be able to exploit this knowledge in therapeutic settings, by limiting T-cell support for the clone or by improving our ability to harness skewed immune reactions against CLL.
